Do you want to read an article? Please log in or register.
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Genitourinary Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 2
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lancet
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators
doi: 10.1016/S0140-6736(24)01756-2
Gastrointestinal Cancer
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial
healthbook TIMES Onco Hema.
Fritsch R
doi: 10.36000/HBT.OH.2024.21.157
ELCC 2025
Lung, Respiratory and Thoracic Cancer
SAKK 16/14: Adding durvalumab to neoadjuvant chemotherapy achieves encouraging EFS and OS in patients with resectable stage IIIA(N2) NSCLC
Gastrointestinal Cancer
Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05)
J Clin Oncol
Li C, Tian Y, Zheng Y, Yuan F, Shi Z, Yang L, Chen H, Jiang L, Wang X, Zhao P, Zhang B, Wang Z, Zhao Q, Dong J, Lian C, Xu S, Zhang A, Zheng Z, Wang K, Dang C, Wu D, Chen J, Xue Y, Liang B, Cheng X, Wang Q, Chen L, Xia T, Liu H, Xu D, Zhuang J, Wu T, Zhao X, Wu W, Wang H, Peng J, Hou Z, Zheng R, Chen Y, Yin K, Zhu Z
doi: 10.1200/JCO.24.00795
Further Publications
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials
Eur J Cancer
Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, Dapper H, Germer CT, Grützmann R, Tim Friede J, Joshua Smith J, Saltz LB, Wu AJ, Weiser MR, Omer D, Ghadimi M, Hofheinz RD, Garcia-Aguilar J, Rödel C, German Rectal Cancer Study Group and the OPRA Consortium
doi: 10.1016/j.ejca.2024.114291
Lung, Respiratory and Thoracic Cancer
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis
Cancer Treat Rev
Aburaki R, Fujiwara Y, Chida K, Horita N, Nagasaka M
doi: 10.1016/j.ctrv.2024.102833
Lung, Respiratory and Thoracic Cancer
Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis
Cancers (Basel)
Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary MA, Goring S, Lozano-Ortega G, Tran M, Varol N, Waser N, Lee JM, Spicer J
doi: 10.3390/cancers16132492
Gynecologic Cancer
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
J Clin Oncol
Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, Ghebre RG, Gressel GM, Lesnock JL, Meyer LA, Moore KN, O'Cearbhaill RE, Olawaiye AB, Salani R, Sparacio D, van Driel WJ, Tew WP
doi: 10.1200/JCO-24-02589
Lung, Respiratory and Thoracic Cancer
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
J Clin Oncol
Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M
doi: 10.1200/JCO-24-02239